Contact

ECHO™-T

Industrialized manufacturing of T therapies

Build on Cellistic’s extensive T-cell experience – including on α/β T-cells and Tregs - to move your immune therapies to scalable therapeutic solution.

Echo T-Cell (Large)

Everything you need, at scale.

Echo™-T unlocks the full potential of allogeneic T-cell therapies by overcoming donor variability and manufacturing limits:

Checkmark IconGenerating engineered iPSC-T cells designed for potency, persistence, and safety

Checkmark IconScaling their production to consistent, clinical-grade output unattainable with donor-derived T cells

Built on a fully industrialized, CMC-integrated platform, Echo™-T gives developers a reliable path from concept to GMP manufacturing with predictable quality, engineered control, and long-term scalability.

Echo™-Treg

Echo™-Treg provides GMP-manufactured, clinically ready iPSC regulatory T cells with natural Treg phenotype, stable identity, and strong suppressive function at scale.

T-CELL process chart
Echo-T Reg

Echo™-Treg

With Cellistic’s Echo™ platform, it’s now possible to manufacture iPSC-derived Tregs with a stable regulatory phenotype and suppressive function comparable to natural Tregs — at the scale, quality, and consistency necessary for commercially viable  autoimmune and inflammatory disease therapies.

It’s possible thanks to a development and manufacturing process developed for a real clinical application moving into in vivo studies, leveraging more than 15 years of iPSC expertise.

What Echo™-T Delivers

GMP-Manufactured iPSC-Tregs delivered at scales suitable for Phase 1 clinical studies: 20 billion+ cells per batch with consistent phenotype and stable functional performance.

Cell Material Icon

High-quality, functional cell material

  • >90% phenotypic purity with strong expression of canonical Treg markers (CD25, CTLA-4, FOXP3, Helios; CD127⁻)
  • Stable regulatory identity, supported by FOXP3 TSDR hypomethylation and maintenance of phenotype under Th1/Th17 inflammatory skewing
  • Robust suppressive function, with dose-dependent inhibition of effector T-cell proliferation comparable to natural/expanded nTregs
  • TCR- and CAR-mediated activation with CAR-specific suppression, demonstrating engineered functionality and predictable performance
  • Batch-to-batch comparability, ensuring reproducible phenotype, potency, and immune-modulatory activity
Document Icon

Comprehensive documentation package

Lightbulb Icons

Integrated IP framework

Group 35336

Consistent, reproducible output

Suppression of effector T cell proliferation
Phenotypic characterization of iPSC-Tregs
Epigenomic profiling
_CELL-CTA-image-2 2-1

Put your T cell manufacturing in trusted, experienced hands.

Echo™-T was built on a platform that can provide precisely what your T cell program demands most: potency, quality, safety, and scalability. Dive deeper into Echo here. 

Artboard 1 1

Harness the full power and potential of T cells for cell therapy.

Checkmark IconAccelerate speed to clinic through a pre-established, iPSC-based GMP manufacturing platform

Checkmark IconBoost scalability using stirred-tank bioreactors

Checkmark IconEnsure regulatory readiness and GMP compliance at our EMA-certified, and FDA and PMDA-compliant manufacturing facility

Checkmark IconReduce process and analytical development challenges with pre-built platform and pre-established starting materials

Checkmark IconSecure clear IP positioning and licensing framework

Cellistic Lab Image

The advantages of putting Cellistic Echo™-T to work.

Qualified iPSC starting materials
Manufacturing starts from pre-established GMP iPSC MCBs offering.

  • Genomic stability, low-passage lines, and full traceability
  • Long-term supply security
  • Optional integration of client-specific edits via Pulse™ and STAR-CRISPR™

Standardized, GMP-aligned differentiation

  • Closed, automated systems minimizing variability
  • Pre-established batch records and qualified GMP raw materials

Scalable 3D bioreactor expansion

  • Controlled, reproducible expansion in automated stirred-tank bioreactors
  • Clinical-scale output exceeding 20B cells per batch
  • Consistent viability, purity, and phenotype maintained across scale
GMP manufacturing & documentation
Produced in Cellistic’s EMA-certified, FDA/PMDA-compliant facility.
  • Full traceability and cGMP batch records
  • Qualified release criteria for identity, purity, potency, sterility, safety
  • A validated vendor supply chain
    ND/IMPD-ready CMC documentation
Group 35338-1

What can Cellistic T cells do for you?

Let’s talk about your plans for cell therapies — and how Cellistic Echo™-T can play an integral role in moving your plans to fruition.